Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study

MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chlorambucil in fludarabine-ineligible patients with chronic lymphocytic leukemia. Patients received rituximab plus bendamustine or rituximab plus chlorambucil every four weeks for six cycles. Rituximab plus...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Haematologica
Asıl Yazarlar: Michallet, Anne-Sophie, Aktan, Melih, Hiddemann, Wolfgang, Ilhan, Osman, Johansson, Peter, Laribi, Kamel, Meddeb, Balkis, Moreno, Carol, Raposo, João, Schuh, Anna, Ünal, Ali, Widenius, Tom, Bernhardt, Alf, Kellershohn, Kerstin, Messeri, Dimitri, Osborne, Stuart, Leblond, Véronique
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Ferrata Storti Foundation 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5865431/
https://ncbi.nlm.nih.gov/pubmed/29419437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.170480
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller